BioSpace News Archive

According to the report, the global addiction treatment market was valued at ~US$ 6 Bn in 2019 and is projected to expand at a CAGR of ~6% from 2020 to 2030.

Pixium Vision SA announces that Lloyd Diamond, Chief Executive Officer of Pixium Vision, will attend the BIOMED EVENT® by Invest Securities, being held on Wednesday, January 26, 2022.

Addex Therapeutics, a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced that CEO, Tim Dyer, will present at the H.C. Wainwright BIOCONNECT Virtual Conference.

Valneva SE, a specialty vaccine company, confirms the previously communicated timelines of its clinical trials and regulatory submissions for its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001.

ONWARD Medical N.V. announces the company and its partners have been awarded nine new patents, seven of them in collaboration with leading neuroscience research laboratories at Caltech, UCLA, EPFL, and University of Louisville.

Basilea Pharmaceutica Ltd., a commercial-stage biopharmaceutical company committed to meeting the needs of patients with infectious diseases and cancer, provided an update on the progress made with both its commercial brands and in its key research and development programs in 2021.

RELIEF THERAPEUTICS reported that the parent company, NRx Pharmaceuticals, Inc., of its collaboration partner with respect to aviptadil, NeuroRx, Inc. has announced that it has submitted an application to the FDA seeking EUA for the use of aviptadil to treat patients with critical COVID-19 who are at immediate risk of death from respiratory failure despite treatment with approved therapy including Remdesivir and who are ineligible for enrollment into the ACTIV-3b NIH-sponsored trial.

Valbiotis updates its calendar, which will gain momentum in 2022 with a number of clinical study results expected during the year concerning the prevention of metabolic and cardiovascular diseases.

Photocure ASA announces that President and Chief Executive Officer, Dan Schneider and Chief Financial Officer, Erik Dahl are scheduled to present a corporate overview and participate in meetings with investors at the H.C. Wainwright BioConnect 2022 Virtual Conference to be held January 10-13, 2022.

Nuance Pharma announced an agreement with Sino Health Pharmaceutical Limited, an affiliated company of Yinglian Pharmaceutical Holdings Group Limited, to fully acquire its 100-percent equity shares and its fully-owned subsidiaries Ying Lian Zhuhai and Ying Lian Germany.